All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View multiple myeloma content recommended for you
Visual abstract | MajesTEC-3: Post hoc analysis of OS, progression, and NRM with Tec-Dara in RRMM
Do you know... Which of the following best describes the findings of a post hoc competing-risk analysis evaluating the contribution of disease progression and NRM to OS in the MajesTEC-3 trial?
In the phase III MajesTEC-3 trial (NCT05083169), teclistamab + daratumumab (Tec-Dara) significantly improved progression-free survival (PFS) and overall survival (OS) compared with daratumumab + pomalidomide + dexamethasone (DPd) or daratumumab + bortezomib + dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).
Here, we present a visual abstract summarizing a post hoc competing-risk analysis, evaluating the contribution of disease progression and non-relapse mortality (NRM) to overall survival (OS) in the MajesTEC-3 trial. The analysis was presented during the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK.
This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
References
- Costa LJ. Overall survival, progression, and non-relapse mortality with teclistamab plus daratumumab (Tec-Dara) vs Dara-based triplets in relapsed/refractory multiple myeloma (RRMM): MajesTEC-3 post hoc analysis. Oral Abstract #OA-49. 23rd International Myeloma Society Annual Meeting and Exposition; Sep 23–26, 2026; Glasgow, UK.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
